Analysis Group Consultants to Contribute 18 New Outcomes Research Presentations at 65th American Society of Hematology Annual Meeting and Exposition
December 1, 2023
Analysis Group consultants will give three oral presentations and exhibit 15 research posters at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition. The conference will take place from December 9 to 12, 2023, in San Diego, California.
Analysis Group’s oral presentations will include:
Effectiveness of Chemo-Immunotherapy (CIT) and Novel Therapies in Second or Later Line of Therapy (2L+) for Patients with Relapsed/Refractory (R/R) Aggressive Large B-Cell Lymphoma (LBCL) (#309)
December 9, 4:30 p.m., Grand Hall C at the Manchester Grand Hyatt San Diego
Coauthors include: Managing Principal Mei Sheng Duh, Vice President Lynn Huynh, and Associates Chi Gao and Ramya Ramasubramanian, and researchers from MD Anderson Cancer Center, Mayo Clinic, Washington University School of Medicine in St. Louis, The University of Iowa Carver College of Medicine, Emory University, Weill Cornell Medicine, University of Miami Health System, University of Rochester Medical Center, AbbVie, and Genmab (sponsor).
Comparison of Time to Next Treatment or Death between Front-Line Daratumumab, Lenalidomide, and Dexamethasone (DRd) and Bortezomib, Lenalidomide, and Dexamethasone (VRd) in Transplant Ineligible Patients with Multiple Myeloma (#543)
December 10, 12:30 p.m., Marriott Grand Ballroom 2–4 at Marriott Marquis San Diego Marina
Coauthors include: Vice President Marie-Hélène Lafeuille, Managers Carmine Rossi and Philippe Thompson-Leduc, and Research Professionals Bronwyn Moore and Anabelle Tardif-Samson, and researchers from Moffitt Cancer Center, Mayo Clinic, and Janssen (sponsor).
Real-World Impact of Luspatercept on Patients with Myelodysplastic Syndromes Requiring Red Blood Cell Transfusions and with Prior Exposure to Erythropoietin-Stimulating Agents: A United States Healthcare Claims Database Study (#916)
December 11, 3:30 p.m., Marriott Grand Ballroom 8–9 at Marriott Marquis San Diego Marina
Coauthors include: Managing Principal Mihran Yenikomshian, Vice President Lynn Huynh, Manager Enrico Zanardo, and Associate Rui Song, and researchers from Carolina Blood and Cancer Care Associates, Minnesota Oncology, VEB Healthcare, the University of New Mexico, and Bristol Myers Squibb (sponsor).
The firm’s posters will be presented in Halls G–H at the San Diego Convention Center, featuring research on the following diseases and conditions:
Treatment Effectiveness with Venetoclax-Based Therapy after Bruton Tyrosine Kinase Inhibitors in Chronic Lymphocytic Leukemia: An International Real-World Study (#1908)
December 9, 5:30–7:30 p.m.
Coauthors include: Managing Principal Annie Guérin, Vice President Irina Pivneva, and Senior Research Professional Talissa Watson, and researchers from Atrium Health Levine Cancer Institute; Columbia University; The Churchill Hospital; University of California, Irvine; Dana-Farber Cancer Institute; Fred Hutchinson Cancer Center; John Theurer Cancer Center; Memorial Sloan Kettering Cancer Center; Rutgers Cancer Institute of New Jersey; Novant Health Cancer Institute; Hôpital Maisonneuve-Rosemont; Cleveland Clinic; the University of Nottingham Medical School; Wilmot Cancer Institute; the University of Massachusetts; Dartmouth Hitchcock Medical Center; Tufts Medical Center; North Carolina Comprehensive Cancer Care Center; the University of Pennsylvania; and AbbVie (sponsor).
Clinical Characteristics, Treatment Patterns, and Outcomes of Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Refractory to Covalent Bruton’s Tyrosine Kinase Inhibitor (BTKi) and Exposed to B-Cell Lymphoma 2 Inhibitor (BCL2i) (#1910)
December 9, 5:30–7:30 p.m.
Coauthors include: Managing Principal Mei Sheng Duh, Vice President Lynn Huynh, Manager Enrico Zanardo, and Analyst Megan Pinaire, and researchers from Dana-Farber Cancer Institute, MSD, and Merck (sponsor).
Ibrutinib Dose Adjustment Does Not Impact Time to Next Treatment in First-Line Patients with Chronic Lymphocytic Leukemia: A Real-World Analysis of Electronic Medical Records from Academic and Non-Teaching Hospitals Using Target Trial Emulation (#1915)
December 9, 5:30–7:30 p.m.
Coauthors include: Managing Principal Patrick Lefebvre, Vice Presidents Marie-Hélène Lafeuille and Bruno Émond, Associate Priyanka Gogna, and Research Professional Bronwyn Moore, and researchers from Atrium Health Levine Cancer Institute, The Ohio State University, and Janssen (sponsor).
Infection Outcomes and Hypogammaglobulinemia in Patients with Chronic Lymphocytic Leukemia Treated with Immunoglobulin Replacement Therapy (#3280)
December 10, 6:00–8:00 p.m.
Coauthors include: Managing Principal Mei Sheng Duh, Vice President Lynn Huynh, and Associate Raj Desai, and researchers from University of California, San Diego; Massachusetts General Hospital Cancer Center; and Mass General Brigham; and Takeda Pharmaceuticals (sponsor).
Correlation between Real-World Progression-Free Survival (rwPFS) and Overall Survival (OS) in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Who Relapsed or Are Refractory, Intolerant, Resistant to Treatment with a Bruton’s Tyrosine Kinase Inhibitor (BTKi) (#4652)
December 11, 6:00–8:00 p.m.
Coauthors include: Managing Principal Mei Sheng Duh, Vice President Lynn Huynh, Manager Enrico Zanardo, and Analyst Megan Pinaire, and researchers from Dana-Farber Cancer Institute, MSD, and Merck (sponsor).
Real-World Evaluation of Treatment Patterns and Clinical Outcomes Among Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Treated with Asciminib in US Clinical Practice (#1809)
December 9, 5:30–7:30 p.m.
Coauthors include: Managing Principal Annie Guérin, Vice President Dominick Latrémouille-Viau, and Manager Carmine Rossi, and researchers from the Medical College of Wisconsin and Novartis Pharmaceuticals (sponsor).
Incremental Healthcare Resource Utilization and Costs Associated with Non-Optimal Treatment in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Treated with Tyrosine Kinase Inhibitors (TKI) in Early Lines of Therapy in the United States (US) (#5908)
December 11, 6:00–8:00 p.m.
Coauthors include: Managing Principal Annie Guérin, Vice President Dominick Latrémouille-Viau, and Manager Hela Romdhani, and researchers from the Georgia Cancer Center at Augusta University and Novartis Pharmaceuticals (sponsor).
Treatment Patterns and Modifications of Tyrosine Kinase Inhibitors (TKI) Therapy in Early Lines in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP): Real-World Analysis from a Large Commercial Claims Database in the United States (US) (#5190)
December 11, 6:00–8:00 p.m.
Coauthors include: Managing Principal Annie Guérin, Vice President Dominick Latrémouille-Viau, and Manager Hela Romdhani, and researchers from the Georgia Cancer Center at Augusta University and Novartis Pharmaceuticals (sponsor).
Comparative Analysis of Clinical Outcomes and Healthcare Resource Utilization (HRU) in Patients (Pts) with Newly Diagnosed (ND) Acute Myeloid Leukemia (AML) Unfit for High-Intensity Chemotherapy Treated with Venetoclax (VEN) Vs Other Therapies: Results from the AML Real World Evidence (ARC) Initiative (#5173)
December 11, 6:00–8:00 p.m.
Coauthors include: Managing Principal Annie Guérin and Manager Rebecca Burne, and researchers from Weill Cornell Medicine, Dana-Farber Cancer Institute, North Carolina Comprehensive Cancer Care Center, the Medical College of Wisconsin, Rabin Medical Center, the O’Neal Comprehensive Cancer Center, Tel Aviv Sourasky Medical Center, the University of Colorado School of Medicine, MedStar Georgetown University Hospital, Duke University School of Medicine, Scripps Health, Hebrew University, Memorial Sloan Kettering Cancer Center, Genentech, and AbbVie (sponsor).
Infection Outcomes and Hypogammaglobulinemia in Patients with Non-Hodgkin Lymphoma Treated with Immunoglobulin Replacement Therapy (#3040)
December 10, 6:00–8:00 p.m.
Coauthors include: Managing Principal Mei Sheng Duh, Vice President Lynn Huynh, and Associate Raj Desai, and researchers from University of California, San Diego; Massachusetts General Hospital Cancer Center; Mass General Brigham; and Takeda Pharmaceuticals (sponsor).
Real-World Retrospective Study of Non-Transfusion Dependent Patients with Myelodysplastic Syndromes Treated with Luspatercept: A Healthcare Claims Database Study (#3808)
December 10, 6:00–8:00 p.m.
Coauthors include: Managing Principal Mihran Yenikomshian, Vice President Lynn Huynh, Manager Enrico Zanardo, and Associate Rui Song, and researchers from the University of New Mexico, Minnesota Oncology, VEB Healthcare, Carolina Blood and Cancer Care Associates, and Bristol Myers Squibb (sponsor).
Estimating Transfusion-Related Medical Costs and Associated Time Burden in Patients with Myelofibrosis: A Comparison of Momelotinib Vs Ruxolitinib Based on Simplify-1 (#4571)
December 11, 6:00–8:00 p.m.
Coauthors include: Managing Principal James Signorovitch, Vice President Gautam Sajeev, Manager Mirko Fillbrunn, and Associate Weilong Li, and researchers from MD Anderson Cancer Center and GSK (sponsor).
Oral Anticoagulant (OAC) Use Among Medicare Patients Newly Diagnosed with Venous Thromboembolism (VTE): Factors Associated with Treatment Status (#2363)
December 9, 5:30–7:30 p.m.
Coauthors include: Vice President Dominick Latrémouille-Viau, Manager Aolin Wang, and Senior Analyst Abigail Zion, and researchers from UPMC Presbyterian Hospital, the University of Pittsburgh School of Pharmacy, Pfizer (sponsor), and Bristol Myers Squibb (sponsor).
Incremental Burden Associated with Dose Escalation in Patients with Paroxysmal Nocturnal Hemoglobinuria Treated with Complement Inhibitors (#5119)
December 11, 6:00–8:00 p.m.
Coauthors include: Managing Principal Annie Guérin, Vice President Dominick Latrémouille-Viau, Associate Raj Desai, and Senior Analysts Shravanthi Seshasayee and Nadia Tabatabaeepour, and researchers from Huntsman Cancer Institute at the University of Utah and Novartis Pharmaceuticals (sponsor).
Real-World Treatment Patterns and Outcomes in Patients with Immune Thrombocytopenia Treated with Avatrombopag in the United States: Real-AVA 2.0 Study Design (#5127)
December 11, 6:00–8:00 p.m.
Coauthors include: Vice Presidents Debbie Goldschmidt and Elyse Swallow and Associate Ali Greatsinger, and researchers from Baptist Health South Florida, Miami Cancer Institute, the Johns Hopkins University School of Medicine, Baylor Scott & White Health, and Sobi (sponsor).